Section Arrow
Quote
FLNA.NASDAQ
- Filana Therapeutics Inc
Quotes are at least 15-min delayed:2026/03/11 10:26 EDT
Regular Hours
Last
 2.058
-0.312 (-13.16%)
Day High 
2.2665 
Prev. Close
2.37 
1-M High
-- 
Volume 
220.90K 
Bid
2.05
Ask
2.06
Day Low
2.03 
Open
2.25 
1-M Low
-- 
Market Cap 
2.26B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.22/-0.55
Enterprise Value
2.26B
Balance Sheet
Book Value Per Share
1.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KALAKala BIO0.3952+0.0953+31.78%-- 
QNCXQuince Therapeutics0.116501+0.015401+15.23%-- 
ACXPAcurx Pharmaceuticals4.0892+1.1892+41.01%-- 
SXTP60 Degrees Pharmaceuticals Inc.2.02+0.15+8.02%-- 
OCGNOcugen2.165+0.395+22.32%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.